43.28 USD
+2.09 (+5.07%)
43.28 USD
0 (0%)
RIGL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. RIGL has an excellent financial health rating, but there are some minor concerns on its profitability. An interesting combination arises when we look at growth and value: RIGL is growing strongly while it also seems undervalued. This makes RIGL very considerable for value and growth investing!
1. Profitability
1.1 Basic Checks
In the past year RIGL was profitable.
In the past year RIGL had a positive cash flow from operations.
In the past 5 years RIGL reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 46.72%, RIGL belongs to the best of the industry, outperforming 99.43% of the companies in the same industry.
The Return On Equity of RIGL (96.34%) is better than 99.43% of its industry peers.
RIGL's Return On Invested Capital of 63.44% is amongst the best of the industry. RIGL outperforms 99.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RIGL has a Profit Margin of 40.17%. This is amongst the best in the industry. RIGL outperforms 96.79% of its industry peers.
RIGL has a better Operating Margin (42.17%) than 98.68% of its industry peers.
The Gross Margin of RIGL (93.10%) is better than 93.77% of its industry peers.
In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
The number of shares outstanding for RIGL has been increased compared to 1 year ago.
RIGL has less shares outstanding than it did 5 years ago.
RIGL has a better debt/assets ratio than last year.
2.2 Solvency
RIGL has an Altman-Z score of -0.48. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
RIGL has a Altman-Z score (-0.48) which is comparable to the rest of the industry.
The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.88, RIGL belongs to the top of the industry, outperforming 93.96% of the companies in the same industry.
A Debt/Equity ratio of 0.25 indicates that RIGL is not too dependend on debt financing.
RIGL has a worse Debt to Equity ratio (0.25) than 66.23% of its industry peers.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.48 |
ROIC/WACC7.14
WACC8.88%
2.3 Liquidity
A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
RIGL has a Current ratio of 2.28. This is in the lower half of the industry: RIGL underperforms 72.83% of its industry peers.
RIGL has a Quick Ratio of 2.14. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
RIGL's Quick ratio of 2.14 is on the low side compared to the rest of the industry. RIGL is outperformed by 72.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 4307.14% over the past year.
RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.13%.
The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 36.89% on average per year.
The Revenue is expected to grow by 15.70% on average over the next years. This is quite good.
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 7.01, which indicates a rather cheap valuation of RIGL.
98.87% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
RIGL is valuated cheaply when we compare the Price/Earnings ratio to 27.17, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.84, which indicates a very decent valuation of RIGL.
98.49% of the companies in the same industry are more expensive than RIGL, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.79. RIGL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.01 | ||
| Fwd PE | 9.84 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.87% of the companies listed in the same industry.
98.49% of the companies in the same industry are more expensive than RIGL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.53 | ||
| EV/EBITDA | 4.79 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
RIGL has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 80.91% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y116.3%
EPS Next 3Y80.91%
5. Dividend
5.1 Amount
No dividends for RIGL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
43.28
+2.09 (+5.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.11%
Inst Owner Change0%
Ins Owners2.59%
Ins Owner Change0%
Market Cap785.53M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target46.24 (6.84%)
Short Float %15.98%
Short Ratio4.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)5.84%
PT rev (3m)18.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)0%
EPS NY rev (3m)17.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.01 | ||
| Fwd PE | 9.84 | ||
| P/S | 2.78 | ||
| P/FCF | 11.53 | ||
| P/OCF | 11.52 | ||
| P/B | 6.68 | ||
| P/tB | 8.51 | ||
| EV/EBITDA | 4.79 |
EPS(TTM)6.17
EY14.26%
EPS(NY)4.4
Fwd EY10.16%
FCF(TTM)3.75
FCFY8.67%
OCF(TTM)3.76
OCFY8.68%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.48 |
F-Score7
WACC8.88%
ROIC/WACC7.14
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y36.89%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year525.53%
EBIT Next 3Y109.33%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
How financially healthy is RIGEL PHARMACEUTICALS INC?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.